Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

12721. Breast cancer screening through mammography. IPE-95/05 (Public report)

Breast cancer screening through mammography. IPE-95/05 (Public report) Breast cancer screening through mammography. IPE-95/05 (Public report) Breast cancer screening through mammography. IPE-95/05 (Public report) Conde Olasagasti J L, Gonzalez Enriquez J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Conde Olasagasti J L, Gonzalez (...) Enriquez J. Breast cancer screening through mammography. IPE-95/05 (Public report) Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). 1995 Authors' objectives To summarise the available evidence on the use of mammography in mass screening for breast cancer. Authors' conclusions The available evidence regarding the efficacy of breast cancer screening by means of periodic mammography in women of 50 years of age or more, is solid and consistent, and is based fundamentally on the results

1995 Health Technology Assessment (HTA) Database.

12722. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review

Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review Hanley J A, McGregor M Record Status This is a bibliographic record of a published health technology assessment from a member (...) of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hanley J A, McGregor M. Screening for cancer of the prostate: an evaluation of benefits, unwanted health effects and costs - nonsystematic review. Montreal: Conseil d'Evaluation des Technologies de la Sante du Quebec (CETS). 1995 Authors' objectives To evaluate the benefits, adverse health effects and costs of screening asymptomatic men for cancer of the prostate. Authors' conclusions From

1995 Health Technology Assessment (HTA) Database.

12723. Costs and effectiveness of prostate cancer screening in elderly men

knowledge about prostate cancer, it may be reasonable for Medicare to consider reimbursement of the screening test. Reimbursement could be seen as ensuring that out-of-pocket screening expenses (however small) not impede well-informed discussion and decision-making between physician and patient. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Aged; Mass Screening; Medicare; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Radiation /therapy Language Published English (...) Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Costs and effectiveness of prostate cancer screening in elderly men Office of Technology Assessment Record Status This is a bibliographic record of a published health technology assessment. The agency responsible for the publication, formerly a member of INAHTA, has subsequently been disbanded. No evaluation of the quality of this assessment has been made

1995 Health Technology Assessment (HTA) Database.

12724. Effectiveness of interventions to enhance physician screening for breast cancer

to enhance physician screening for breast cancer. Journal of Family Practice 1995; 40(2): 162-171 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Breast Neoplasms /prevention & Controlled Clinical Trials as Topic; Female; Humans; Mammography /statistics & Mass Screening /statistics & Physicians /statistics & Referral and Consultation /statistics & control; numerical data; numerical data; numerical data; numerical data AccessionNumber 12000008135 Date bibliographic record published 31/08 (...) Effectiveness of interventions to enhance physician screening for breast cancer Effectiveness of interventions to enhance physician screening for breast cancer Effectiveness of interventions to enhance physician screening for breast cancer Mandelblatt J, Kanetsky P A Authors' objectives To review articles assessing the effectiveness of interventions to enhance physician breast cancer screening behaviour. Searching MEDLINE was searched for studies published between January 1980 and April 1993

1995 DARE.

12725. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money

family history for breast cancer. Tumour characteristics were given for each participant. Setting Secondary care. The economic study was carried out in Philadelphia, Pennsylvania,USA Dates to which data relate Effectiveness data were collated during the period January 1991 to December 1992. Price years were not stated. Source of effectiveness data Effectiveness data were derived from a single study. Link between effectiveness and cost data The costing was undertaken retrospectively on the same (...) predictive value (PPV). Side effects of scanning were not addressed. Effectiveness results Bone scanning had an initial sensitivity of 100%, with a specificity of 86.8%. Initial bone scans had a positive predictive value of only 11% for synchronous proof of bone metastases.63 (20%) of 316 initial bone scans were interpreted as positive or suspicious for malignancy.7 women (2%) were found to have bone metastases. A single patient in whom there was no clinical suspicion of distant disease had bone

1995 NHS Economic Evaluation Database.

12726. Screening for colorectal cancer: what are the costs?

Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Screening for colorectal cancer: what are the costs? Weller D, Moss J, Hiller J, Thomas J, Edwards J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The fecal occult blood test (FOBT) as a method for screening for the detection of colorectal cancer. Type of intervention Screening. Economic study type Cost-effectiveness study. Study population Patients screened for colorectal cancer. Setting The practice setting is the community with follow up in general practice and institutions as required. The study was undertaken in South Australia. Dates to which data relate Effectiveness and resource data were collected

1995 NHS Economic Evaluation Database.

12727. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation

and quantities were not reported separately. Source of funding None stated. Bibliographic details Rajan R, Gafni A, Levine M, Hirsh J, Gent M. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation. Journal of Clinical Oncology 1995; 13(1): 42-46 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Breast Neoplasms /complications /drug therapy; Canada; Female; Health Care Costs; Humans; Thromboembolism (...) Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation Rajan R, Gafni A, Levine M, Hirsh J, Gent M Record

1995 NHS Economic Evaluation Database.

12728. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis

Patients with malignant pain from pancreatic and other intra-abdominal cancers were included. Outcomes assessed in the review The study results were classified into three major categories of NCPB relief: complete, partial and minimal/no pain relief. These results were further categorised as acute (up to 2 weeks) or long-term (2 or more weeks). The long-term effect, where possible, was divided according to period of time from NCPB (within 3 months versus beyond 3 months, and also up to time of death (...) ' conclusions The present analysis suggests that NCPB is likely to have long-term analgesic efficacy for pancreatic and other types of intra-abdominal cancer. Adverse effects are common but transient. Further RCTs are necessary to compare NCPB to other analgesic treatments, such as systemic or spinal delivery of opioids, and to evaluate whether it may be appropriate to use it at the first appearance of pain with intra-abdominal malignancy. CRD commentary The literature search is limited to English language

1995 DARE.

12729. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies

S C, MacLennan A H, Ryan P. Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies. Medical Journal of Australia 1995; 162(9): 491-493 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Colorectal Neoplasms /chemically induced /epidemiology; Confidence Intervals; Estrogen Replacement Therapy /adverse effects; Female; Humans; Risk Factors AccessionNumber 11995000761 Date bibliographic record published 27/06/1996 Date abstract record published (...) Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies Colorectal cancer and oestrogen replacement therapy: a meta-analysis of epidemiological studies MacLennan S C, MacLennan A H, Ryan P Authors' objectives To determine if non-contraceptive oestrogen replacement therapy alters the risk of colorectal cancer. Searching MEDLINE was searched from 1974 to 1993

1995 DARE.

12730. Prevention of skin cancer: a review of available strategies

skin cancer-related knowledge, sun-related behaviour, the reduction in skin cancer incidence and the reduction in mortality from malignant melanoma. How were decisions on the relevance of primary studies made? The author does not state how the papers were selected for the review, or how many of the reviewers performed the selection. Assessment of study quality The author does not state that they assessed validity. Data extraction The author does not state how the data were extracted for the review (...) . The probability of developing a new non-melanoma skin cancer was not significantly different between the groups during 5 years follow-up. Effectiveness of low-dose isotretinoin (10 mg daily) on the prevention of recurrence of basal cell carcinoma was assessed in a RCT: 981 patients were followed-up for 6 months to 3 years, and there was no significant difference between the isotretinoin and the placebo groups in the cumulative incidence of new lesions. For secondary prevention, the evidence regarding

1995 DARE.

12731. Hormone replacement therapy and endometrial cancer risk: a meta-analysis

Hormone replacement therapy and endometrial cancer risk: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

1995 DARE.

12732. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study

not be robust. Bibliographic details Marino P, Preatoni A, Cantoni A, Buccheri G. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995; 13(1): 1-12 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy; Humans; Lung Neoplasms /drug therapy; Randomized (...) Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study Marino P, Preatoni A, Cantoni A, Buccheri G Authors' objectives To compare single-agent

1995 DARE.

12733. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis

control trial. Control Clin Trials 1981;2:31-49. Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /radiotherapy /therapy; Cisplatin /therapeutic use; Combined Modality Therapy; Humans; Lung Neoplasms /drug therapy /radiotherapy /therapy AccessionNumber 11995002271 Date bibliographic record published 31/08/1996 Date abstract record published 31/08/1996 Record Status This is a critical (...) Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis Marino P, Preatoni A, Cantoni A Authors

1995 DARE.

12734. Adjuvant therapy of node-negative breast cancer

year of life saved in women with node negative breast cancer are: $15,400 for chemotherapy in premenopausal women, $18,800 for chemotherapy in postmenopausal women, and $11,400 for tamoxifen in premenopausal women with estrogen receptor positive tumours. Authors' conclusions Adjuvant therapy improves disease-free survival in both premenopausal and postmenopausal patients with estrogen receptor negative tumours, and improves overall survival in this postmenopausal group. For patients with tumours (...) , Hillner BE. The efficacy and cost effectiveness of adjuvant therapy of early breast cancer in premenopausal women. J Clin Oncol 1993;11:771-776. Indexing Status Subject indexing assigned by NLM MeSH Breast Neoplasms /classification /mortality /pathology /therapy; Carcinoma in Situ /mortality /pathology /therapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Lymph Node Excision; Mastectomy, Segmental; Meta-Analysis as Topic; Prognosis; Randomized Controlled Trials as Topic

1995 DARE.

12735. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation

untransfused and transfused, who experienced or did not experience the adverse outcome. Specific interventions included in the review Perioperative transfusion. Participants included in the review Patients undergoing surgery for cancer of the colorectum, breast, head and neck, lung, prostate and stomach. For a tumour site to be included in the review at least five articles had to be identified. Outcomes assessed in the review The outcomes assessed were cancer recurrence, death due to cancer recurrence (...) adjustment for the effect of confounding factors. The crude increase in the risk of an adverse outcome ranged from 6% in breast cancer to 262% in head and neck carcinomas, and was significant in all cancer sites except for breast. However, this study is not able to attribute this effect to either the transfusion effect or effect(s) of uncontrolled confounders. A number of the original studies found that by controlling for confounding they decreased the effect size of the transfusion. Further randomised

1995 DARE.

12736. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

, Alkylating /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /mortality /radiotherapy /surgery; Cisplatin /therapeutic use; Combined Modality Therapy; Humans; Lung Neoplasms /drug therapy /mortality /radiotherapy /surgery; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Survival Rate; Treatment Outcome AccessionNumber 11995002726 Date bibliographic record published 31/01/1997 Date abstract (...) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Non-small Cell Lung Cancer Collaborative Group Authors' objectives To evaluate

1995 DARE.

12737. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer

lung cancer. Lung Cancer 1995; 12(Supplement 1): S147-S154 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /mortality; Humans; Lung Neoplasms /drug therapy /mortality; Palliative Care; Randomized Controlled Trials as Topic /statistics & numerical data AccessionNumber 11995001874 Date bibliographic record published 19/05/1996 Date abstract record published 19/05/1996 Record (...) Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer Souquet P J, Chauvin F, Boissel J P, Bernard J P Authors' objectives To determine the usefulness

1995 DARE.

12738. Whole grain intake and cancer: a review of the literature

Whole grain intake and cancer: a review of the literature Whole grain intake and cancer: a review of the literature Whole grain intake and cancer: a review of the literature Jacobs D R, Slavin J, Marquart L Authors' objectives To test the hypothesis that higher whole grain intake would be associated with decreased cancer and risk of coronary heart disease (CHD). Searching MEDLINE was searched and the references of retrieved papers were reviewed. Study selection Study designs of evaluations (...) , gastric and endometrial cancer and CHD. How were decisions on the relevance of primary studies made? Not stated, but the articles were selected based on the occurrence of phrases 'wholegrain' or 'wholemeal' and 'cancer' or 'coronary heart disease'. Assessment of study quality [A: All articles located were included and classified according to study design.] The authors do not state how the papers were assessed for validity, or how many of the authors performed the validity assessment. Data extraction

1995 DARE.

12739. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer

, hydroxyurea, bleomycin, cyclophosphamide, and 6 mercaptopurine. Participants included in the review People with head and neck cancer of any type or location were eligible for inclusion in the review. Outcomes assessed in the review The studies had to report survival, disease-free survival or local control to be included in the review. How were decisions on the relevance of primary studies made? The author does not state how the papers were selected for the review, although as there is only one author (...) An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer Munro A J Authors' objectives The primary objective was to discover whether the addition of chemotherapy to definitive standard therapy improved survival in patients with cancer of the head and neck. The secondary

1995 DARE.

12740. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary

A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary Allen D G, Heintz A P, Touw F W Authors' objectives A meta-analysis of retrospective studies was performed to determine the value of cytoreductive surgery for stage III and stage IV ovarian cancer, separately. Searching (...) with no residual disease, less than or equal to 2 cm, and greater than 2cm residual disease, considered separately for stage III and stage IV ovarian cancer. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the authors performed the selection. Assessment of study quality The authors do not state that they assessed validity. Data extraction The authors do not state how the data were extracted for the review, or how

1995 DARE.